Lupus Nephritis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Aurinia Pharmaceuticals, Otsuka Pharmaceutical, GlaxoSmithKline, AstraZeneca, Roche

The Lupus Nephritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lupus Nephritis pipeline products will significantly revolutionize the Lupus Nephritis market dynamics.

DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Lupus Nephritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lupus Nephritis Market Forecast
https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Lupus Nephritis Market Report:
• The Lupus Nephritis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In February 2025, the FDA approved Allogene Therapeutics' investigational new drug (IND) application for ALLO-329, an allogeneic CAR-T cell therapy. The Phase 1 RESOLUTION trial is expected to commence in mid-2025, targeting autoimmune diseases such as systemic lupus erythematosus (SLE), lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.
• In November 2024, Adicet Bio reported that the initial patient with lupus nephritis (LN) has received a dose in its Phase I clinical trial assessing ADI-001 for autoimmune disorders.
• In November 2024, Kyverna Therapeutics revealed plans to share updated clinical data from lupus nephritis (LN) patients treated with KYV-101 in its ongoing KYSA-1 and KYSA-3 Phase I/II trials, as well as through named patient treatments.
• In 2023, the United States contributed an estimated USD 1,500 million.
• GAZYVA/GAZYVARO (obinutuzumab) and SAPHNELO (anifrolumab) are among the promising emerging therapies poised to significantly impact and potentially reshape the lupus nephritis treatment landscape.
• By 2034, SAPHNELO (anifrolumab) is projected to lead the revenue among emerging lupus nephritis therapies in the United States, generating over USD 300 million.
• In the overall lupus nephritis market across the 7MM, the United States held the largest share-exceeding 80% in 2023-followed by Japan and Spain.
• In 2023, the United States held the largest portion of the market among the 7 Major Markets (7MM), amounting to 60%, with the UK following closely behind.
• In 2023, the market size for lupus nephritis in the EU4 countries and the UK was about USD 300 million.
• Pennesi and Benvenuto (2023) observed that lupus nephritis is more prevalent among children, occurring in 32-55% of cases, and tends to be more severe in this age group.
• According to DelveInsight, the total number of existing cases of systemic lupus erythematosus in the 7 Major Markets (7MM) was approximately 660,000 in 2023.
• Key Lupus Nephritis Companies: Hoffmann-La Roche, Genentech, Inc., Astrazeneca, Equillium, Novartis Pharmaceuticals, BeiGene, Boehringer Ingelheim, and others
• Key Lupus Nephritis Therapies: Obinutuzumab, Mycophenolate Mofetil, Anifrolumab, Itolizumab, Myfortic, Zanubrutinib, and others

Lupus Nephritis Overview
Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease. It specifically refers to inflammation of the kidneys caused by the immune system mistakenly attacking the kidney tissues.

Get a Free sample for the Lupus Nephritis Market Report:
https://www.delveinsight.com/report-store/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lupus Nephritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Lupus Nephritis Epidemiology Segmentation:
The Lupus Nephritis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Lupus Nephritis
• Prevalent Cases of Lupus Nephritis by severity
• Gender-specific Prevalence of Lupus Nephritis
• Diagnosed Cases of Episodic and Chronic Lupus Nephritis

Download the report to understand which factors are driving Lupus Nephritis epidemiology trends @ Lupus Nephritis Epidemiological Insights
https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lupus Nephritis Market
The dynamics of the Lupus Nephritis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Obinutuzumab, Myfortic, and others during the forecasted period 2020-2034.

Lupus Nephritis Therapies and Key Companies
• LUPKYNIS (voclosporin): Aurinia Pharmaceuticals/Otsuka Pharmaceutical
• BENLYSTA (belimumab): GlaxoSmithKline
• SAPHNELO (anifrolumab): AstraZeneca
• GAZYVA/GAZYVARO (obinutuzumab): Roche
• Obinutuzumab: Hoffmann-La Roche
• Mycophenolate Mofetil: Genentech, Inc.
• Anifrolumab: Astrazeneca
• Itolizumab: Equillium
• Myfortic: Novartis Pharmaceuticals
• Zanubrutinib: BeiGene

To know more about Lupus Nephritis treatment, visit @ Lupus Nephritis Medications
https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lupus Nephritis Market Drivers
• Increase in research activities
• Increasing disease prevalence
• Surge in a number of clinical studies

Lupus Nephritis Market Barriers
• High Lupus Nephritis Treatment costs
• Need for novel Lupus Nephritis therapeutics
• Surge in a number of clinical studies
• Need for targeted treatment regimen

Scope of the Lupus Nephritis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Lupus Nephritis Companies: Hoffmann-La Roche, Genentech, Inc., Astrazeneca, Equillium, Novartis Pharmaceuticals, BeiGene, Boehringer Ingelheim, and others
• Key Lupus Nephritis Therapies: Obinutuzumab, Mycophenolate Mofetil, Anifrolumab, Itolizumab, Myfortic, Zanubrutinib, and others
• Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
• Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Lupus Nephritis Unmet Needs, KOL's views, Analyst's views, Lupus Nephritis Market Access and Reimbursement

Discover more about therapies set to grab major Lupus Nephritis market share @ Lupus Nephritis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Lupus Nephritis Market Report Introduction
2. Executive Summary for Lupus Nephritis
3. SWOT analysis of Lupus Nephritis
4. Lupus Nephritis Patient Share (%) Overview at a Glance
5. Lupus Nephritis Market Overview at a Glance
6. Lupus Nephritis Disease Background and Overview
7. Lupus Nephritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Lupus Nephritis
9. Lupus Nephritis Current Treatment and Medical Practices
10. Lupus Nephritis Unmet Needs
11. Lupus Nephritis Emerging Therapies
12. Lupus Nephritis Market Outlook
13. Country-Wise Lupus Nephritis Market Analysis (2020-2034)
14. Lupus Nephritis Market Access and Reimbursement of Therapies
15. Lupus Nephritis Market Drivers
16. Lupus Nephritis Market Barriers
17. Lupus Nephritis Appendix
18. Lupus Nephritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Lupus Nephritis Pipeline https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Lupus Nephritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Lupus Nephritis market. A detailed picture of the Lupus Nephritis pipeline landscape is provided, which includes the disease overview and Lupus Nephritis treatment guidelines.

Lupus Nephritis Epidemiology https://www.delveinsight.com/report-store/lupus-nephritis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Lupus Nephritis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Lupus Nephritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Optical Coherence Tomography Devices Market: https://www.delveinsight.com/report-store/optical-coherence-tomography-oct-devices-market
• Prediabetes Market: https://www.delveinsight.com/report-store/prediabetes-market
• Scoliosis Market: https://www.delveinsight.com/report-store/scoliosis-market
• Psoriasis Market: https://www.delveinsight.com/report-store/psoriasis-market
• Tendinitis Market: https://www.delveinsight.com/report-store/tendonitis-market
• Vascular Closure Devices Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Hydrocephalus Market: https://www.delveinsight.com/report-store/hydrocephalus-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.